Biophytis SA announced the signature of an exclusive license agreement with Blanver, one of the leading and most trusted pharmaceutical company in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin American including, but not limited to Brazil, Mexico, Argentina and Colombia. The agreement provides that Blanver will be responsible for the registration, marketing and commercialization of BIO101 (20- Hydroxyecdysone) in its various indications: obesity, respiratory infections due to Covid-19,arcopenia and Duchenne Muscular Dystrophy (DMD) - once Biophytis has successfully completed the planned clinical development programmes for its drug candidate. With 40 years of history, Blanver has become an expert in infectious diseases, osteoporosis and metabolic disorders, which is a perfect match with Biophytis.

In addition of Brazil, Blanver has an extensive network of unique distributors that covers the whole Latin America region. Under the terms of this partnership, Biophytis will be able to receive up to EUR108 million including an upfront payment and further additional payments if certain objectives are achieved. Biophytis is also eligible to receive double-digit royalties on net sales of BIO101 (20-Hydroxy Evidenceysone) generated in the collaboration territory, after obtaining future marketing authorisations.

This collaboration in one of the main pharma regions in the world, underscores the potential of BIO101 (20 -Hydroxyecdysone) which is based on the positive clinical results already obtained in several indications.